WellINFORMED. From the PRESIDENT S DESK. Every Little Thing Brings BIG OUTCOMES.
|
|
- Erik Carroll
- 5 years ago
- Views:
Transcription
1 WellINFORMED From the PRESIDENT S DESK At WellDyneRx, we believe that every little thing brings big outcomes. We re committed to optimizing and enhancing every health plan, every prescription fill, and every interaction we have no matter how small. That commitment shows in our 2017 Drug Trend Report. The numbers included within it underscore our goal to drive improved patient outcomes and lower costs. I hope you were able to join our live 'May 24th' 2017 Drug Trend Report webinar and see first-hand how we're helping our clients solve key problems. The proof is in the impressive outcomes we shared during this event. In this edition of Well Informed, you ll learn more about our 2017 Drug Trend Report as well as our response to a recent 60 Minutes story about PBM concerns and high drug prices. We ll also highlight some July 1st formulary changes, client FAQs, current HIV treatments, and our new WellManaged - Respiratory program. Additionally, we ve included information about industry events we will attend as well as new FDA-approved drugs. We appreciate your business and hope you find this information interesting and beneficial. As always, your feedback is important to us, please let us know if you have any questions or comments. Sincerely, Zach Johnson Every Little Thing Brings BIG OUTCOMES. May 2018
2 2017 Drug Trend Report Webinar REPORTS In 2017, with the help of our WellManaged clinical programs and strategic formulary designs, WellDyneRx helped clients maintain a low 1.2% rate of growth in per-person prescription drug spend. We were able to contain costs for our clients despite significant increases in utilization of specialty medications and double digit price inflation in many drug categories. These achievements and more are covered in detail in our new 2017 Drug Trend Report. Total drug trend is made up of the utilization and unit cost of drugs, and can be further subdivided into traditional and specialty drug categories, as well as the top therapeutic drug classes for each. The top overall category for increases in spend was the specialty drug category of Inflammatory Conditions, which includes disease states such as rheumatoid arthritis, psoriasis, Crohn s disease, and ulcerative colitis. The most commonly used drugs within this category are Humira and Enbrel, and they account for almost 50% of the utilization. The top traditional drug category, and the second top category overall, was diabetes. Diabetes accounted for almost 12% of total spend, and the increases in trend were driven largely by unit cost increases in insulin. To actively manage traditional drug spend, clients can implement our WellManaged-Formulary programs, such as WellManaged-Generics, WellManaged-Preferred Brands, and WellManaged- Hyperinflationary Drugs. Also, while WellManaged- Diabetes and WellManaged-Opioids are focused primarily on clinical outcomes, our 2017 Drug Trend Report demonstrates that they also deliver financial benefits. In 2017, WellManaged-Diabetes helped clients achieve a negative unit cost trend while increasing medication adherence and reducing hemoglobin A1c, the primary health outcome related to the management of diabetes. In the same year, WellManaged-Opioids helped clients achieve a 36% lower average cost per 30-day supply of opioid medication. To learn more about the WellDyneRx 2017 Drug Trend Report and the efficacy of our clinical programs and utilization management strategies, listen to a recording of our recent webinar. Click Here to Listen Drug Trend Report Webinar During the webinar, WellDyneRx s clinical leaders discussed data trends, presented significant findings and analyzed the highlights of the 2017 Drug Trend Report. 2
3 WellDyneRx Response to Recent PBM News Coverage On a recent episode of 60 Minutes, Lesley Stahl did a segment called The Rockford File where she investigated a pending class-action lawsuit brought by the city of Rockford, Illinois against pharmaceutical manufacturer Mallinckrodt and their pharmacy benefit manager (PBM). The case involves a drug called HP Acthar that originally sold for $40 a vial in 2001, but today is sold for more than $40,000. Knowing about this and other similar medications that have experienced significant price hikes in recent years, WellDyneRx launched the WellManaged Hyperinflationary Drugs program. This program monitors the pricing and clinical relevance of new and existing medications. Drugs are added to an exclusion list if they are significantly more costly than medications offering similar clinical outcomes. To date, WellDyneRx has identified 243 medications which are part of the Hyperinflationary Drugs program. Unfortunately, many of our clients have not implemented this program and are at risk of paying too much for medications that WellDyneRx deems wasteful because there are less expensive, clinicallyequivalent options available. FOR MORE INFORMATION please visit WellDyneRx.com or call Every Little Thing Brings BIG OUTCOMES Quality Care Is Our Prescription You may have seen a piece by Lesley Stahl that ran on CBS 60 Minutes recently entitled The Rockford File. In it, she discusses a pending class-action lawsuit brought by the city of Rockford, Illinois against pharmaceutical manufacturer Mallinckrodt and their Pharmacy Benefits Manager (PBM). The reason? One drug in particular: HP Acthar. In 2001, Acthar sold for about $40 a vial. Today, it costs more than $40,000 an increase of 100,000 percent. These soaring costs have forced the city of Rockford to forego vital city improvements in staffing for police and firefighters, effectively pushing the city s finances to the brink. As a PBM, WellDyneRx would like to take this opportunity to highlight our approach and the different outcomes we ve generated when it comes to HP Acthar. Knowing about this and other similar medications that have had high price increases, WellDyneRx decided to proactively combat this problem by creating the WellManaged Hyperinflationary Drugs program. The WellManaged Hyperinflationary Drugs program monitors the pricing and clinical relevance of new and existing medications. Drugs are added to an exclusion list if they are significantly more costly than medications offering similar clinical outcomes. To date, WellDyneRx has identified 243 medications which are part of the Hyperinflationary Drugs program. Unfortunately, many of our clients have not implemented this program and are at risk of paying too much for medications that WellDyneRx deems wasteful because there are less expensive, clinically-equivalent options available WellDyneRx Read WellDyneRx s full response to the 60 Minutes episode here. 3 *60 Minutes image, property of CBS News, not WellDyneRx..
4 We re Listening! Client FAQs As one of the nation s premier PBMs, WellDyneRx is extremely fortunate to have built such a robust array of unique clinical and cost containment programs as seen in our WellManaged programs. As a whole, they allow us to do two things: one, provide outstanding service to both clients and members. And two, they boost our ability to be flexible so we can give our clients the strategic business advantages they need to be successful. All of this is important to note because we frequently get asked the same questions by our clients, often around issues addressed by our umbrella of WellManaged programs. So, for the purpose of this article, we thought it would be helpful to highlight a few of those questions and show how our WellManaged Clinical and WellManaged Formulary Programs help to answer them. Question: How do you manage your plan spend and address the growing cost of specialty medications? Answer: WellDyneRx s patented Intercept Shared Savings Program helps clients control specialty spend by shifting drug costs to other payment avenues. Clients achieve a net effective AWP discount of 30% Clients realize a $512 lower cost per specialty drug Clients realized savings of $45.05 PMPY Saved clients over $15 million in 2017 (continued on next page) 4
5 We re Listening! Client FAQs Question: (continued) What is the potential savings for the plan/member and the potential disruption to the member? Answer: Our WellManaged Formulary Program brings the most balanced benefit design to the market, with formulary choice as its foundation. WellManaged programs help to positively influence total healthcare costs by managing unit cost of prescriptions with Prior Authorizations (PAs), Quantity Limits (QLs), and step edits. Member engagement to promote quality of care through our full suite of programs Diabetes Respiratory Opioids Hepatitis C As far as disruption to our members, we point to this fact: US Specialty Care has been recognized as the specialty pharmacy with the highest patient satisfaction ratings across the United States for two years in a row. Question: What are you doing in regard to the opioid epidemic? Answer: Our WellManaged Opiods Program takes a comprehensive approach to addressing this growing problem. Maintaining access to opioid medications while prioritizing patient safety and controlling costs. Real time point of service (POS) cumulative morphine equivalent dose (MED) edits Prior Authorization for targeted high-risk medications Proprietary risk stratification evaluation Physician communication on at-risk members Cancer, end-of life care, or hospice patients are excluded Do you have more questions? Let us know! 5
6 Effective July 1, 2018: Formulary Changes On July 1, 2018, the formulary status of the following medications will change. WellDyneRx is committed to offering our clients and plan participants the best prescription benefit options at the lowest cost. To accomplish this, the clinical team at WellDyneRx partners with a Pharmacy and Therapeutics (P&T) committee to evaluate the efficacy and safety of new drug approvals and to review clinical components of existing medications. These drugs were evaluated during the March 2018 P&T Committee meeting and final determinations were based upon multiple factors, including safety profile, therapeutic impact, medical necessity, and cost-effectiveness. Formularies play a critical role in prescription drug benefits as they guide medication therapy choices. The table below outlines the changes to the WellDyneRx Clinical Focus formulary. Clinical Focus Formulary Brand Name Generic Name Typical Use 2018 Tier Change Preferred Alternatives Dexilant dexlansoprazole Acid Reflux Preferred N/A Cialis tadalafil Erectile Dysfunction Preferred N/A Lo Loestrin Fe norethinedrone acetate; ethinyl estradiol; ferrous fumarate Contraception Preferred N/A Steglatro ertugliflozin Type 2 Diabetes Mellitus Preferred N/A Segluromet ertugliflozin; metformin Type 2 Diabetes Mellitus Preferred N/A Jardiance empagliflozin Type 2 Diabetes Mellitus Non-preferred Farxiga, Steglatro Synjardy Synjardy XR empagliflozin; metformin Type 2 Diabetes Mellitus Non-preferred Xigduo, Segluromet Ibrance palbociclib Cancer Non-preferred Kisqali Gleevec imatinib Cancer Non-preferred imatinib Copaxone glatiramer Multiple Sclerosis Non-preferred glatiramer Omnitrope somatropin Growth Hormone Excluded Norditropin, Genotropin This list is not comprehensive and does not contain every possible formulary alternative. Formulary items are subject to change. 6
7 Effective July 1, 2018: Formulary Changes The table below outlines the changes to the WellDyneRx Clinical Outcomes formulary. Clinical Outcomes Formulary Brand Name Generic Name Typical Use 2018 Tier Change Preferred Alternatives Steglatro ertugliflozin Type 2 Diabetes Mellitus Preferred N/A Segluromet ertugliflozin; metformin Type 2 Diabetes Mellitus Preferred N/A Jardiance empagliflozin Type 2 Diabetes Mellitus Non-preferred Farxiga, Steglatro Synjardy Synjardy XR empagliflozin; metformin Type 2 Diabetes Mellitus Non-preferred Xigduo, Segluromet Ibrance palbociclib Cancer Non-preferred Kisqali Gleevec imatinib Cancer Excluded imatinib Copaxone glatiramer Multiple Sclerosis Excluded glatiramer This list is not comprehensive and does not contain every possible formulary alternative. Formulary items are subject to change. We constantly evaluate our formulary to match patients with the most effective treatments. If there s a better or more practical prescription option for our clients and members, we tell them. With that transparency comes trust. That s the WellDyneRx approach. 7
8 May is Hepatitis Awareness Month The month of May is designated as Hepatitis Awareness Month in the United States, and May 19th was Hepatitis Testing Day. During May, the Centers for Disease Control and Prevention (CDC) and its public health partners work to shed light on this hidden epidemic by raising awareness of viral hepatitis and encouraging priority populations to get tested. The hepatitis C virus (HCV) is among the most common bloodborne viral infections in the United States. Approximately 2.7 to 3.9 million Americans are currently living with a chronic form of this infection. The risk of infection with HCV is increased if a person: Shared needles to inject drugs or straws to inhale them Obtained tattoos or body piercings in an unclean environment using unsterile equipment Worked in a place where they came in contact with infected blood or needles, for example, healthcare workers Received a blood transfusion or organ transplant before July 1992 Received a blood product for clotting problems made before 1987 Needed to have blood filtered by a machine (hemodialysis) for a long period of time because their kidneys weren t working Were born to a mother with HCV Encourage your plan members to get tested if they are part of this priority population. To learn more about how WellDyneRx helps our clients manage the costs associated with HCV treatments, read our case study. 8
9 Current Management of Human Immunodeficiency Virus (HIV) According to the Centers for Disease Control and Prevention (CDC), more than 1.1 million Americans are infected with the human immunodeficiency (HIV) virus and roughly 14% of them are unaware of their infection. Since the start of the epidemic, there have been more than 700,000 deaths in the United States due to the progression of HIV to acquired immunodeficiency syndrome (AIDS). Currently, there are two types of the HIV virus worldwide, with HIV-1 being the most prevalent. Management of HIV is intricate and requires rapid initiation of antiretroviral therapy (ART) at the time of diagnosis. Due to the nature of the virus mutating quickly, complex multi-drug regimens are required for effective viral suppression. The primary goals of treatment include controlling viral replication, preventing resistance, decreasing medication side effects and pill burden, minimizing long-term co-morbidities and preventing new infections. In order to achieve these goals, adherence must be at least 95% to the patients prescribed ART. Early treatment must involve patient engagement to reveal any barriers influencing the patient s ability to adhere to the ART and approaches should be tailored to an individual s needs. Current Therapies for HIV and Looking Ahead HIV medications are grouped into seven drug classes according to their mechanism of action. These drug classes include non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, integrase strand transfer inhibitors (INSTIs), and post-attachment inhibitors. An individual s first HIV regimen usually includes a 3-drug regimen consisting of two NRTI s plus an INSTI or an NNRTI or a PI boosted with cobicistat. It is very common for patients to switch from one regimen (or combination of drugs) to another due to intolerance or development of resistance. Therefore, patient education and coordinated multidisciplinary care are paramount to successful and effective ART therapy. The ART pipeline remains robust with the development of new co-formulations to address issues with adherence and side effects along with biologics to treat specific populations with multidrug resistant HIV. Since the fourth quarter of 2017, several new drugs received FDA-approval to target safety and efficacy along with validating two-drug regimens as a durable maintenance treatment. (continued on next page) 9
10 Current Management of Human Immunodeficiency Virus (HIV) (continued) The table below illustrates the most recent FDA drug approvals and provides a preview of agents currently under investigation in the pipeline. Additionally, HIV vaccines and passive immunity models are currently under investigation with a goal of curing HIV. To date, there is no vaccination proven to be fully effective against preventing the spread of HIV. In 2009, a landmark trial known as RV144 in Thailand provided the first signal of HIV vaccine efficacy. Several current phase II clinical trials used findings from this study to supplement research. More recently, passive immunization models involving injections or IV infusions with broad neutralizing antibodies (bnabs) appear promising. While developing an HIV vaccination is challenging due to characteristic rapid mutations, significant progress is underway. Drug Manufacturer Mechanism Route Approval Juluca (dolutegravir and rilpivirine) Symfi Lo (efavirenz/ lamivudine/tdf) ViiV Healthcare INSTI/NNRTI Oral 11/21/2017 Mylan NNRTI/NRTI/NRTI Oral 2/5/2018 Biktarvy (BIC/FTC/TAF) Gilead INSTI/NRTI/NRTI Oral 2/7/2018 Cimduo (lamivudine/tdf) Mylan NRTI/NRTI Oral 2/28/2018 Trogarzo (ibalizumab uiyk) Theratechnologies/TaiMed Post-Attachment Inhibitor IV 3/6/2018 Symfi (efavirenz/ lamivudine/tdf) Mylan NNRTI/NRTI/NRTI Oral 3/6/2018 TBD (COBI/DRV/FTC/TAC) Janssen Booster/PI/NRTI/NRTI Oral 7/25/2018 TBD (doravirine/ lamivudine/tdf) TBD (cabotegravir/ rilpivirine) Merck NNRTI/NRTI/NRTI Oral 2018 ViiV Healthcare INSTI/NNRTI IM 2019 TBD (PRO-140) CytoDyne Viral Entry Inhibitor SC 2019 (TBD To Be Determined) 10
11 WellManaged - Respiratory Program The WellManaged Respiratory program helps clients control costs, ensure appropriate utilization, and improve the overall quality of care for asthma and chronic obstructive pulmonary disease (COPD) patients. While uncontrolled asthma can lead to increased emergency room visits, hospitalizations and fatalities, COPD is the third leading cause of death in the United States. Due to the prevalence of these diseases in our society and their associated treatment costs, asthma and COPD medications are typically included in the top five cost drivers for our clients. Therefore, the newly launched WellManaged Respiratory program includes an aggressively-managed formulary, adherence interventions, and patient education to ensure optimal clinical outcomes while containing costs. Asthma is a respiratory condition marked by spasms in the bronchi of the lungs, causing difficulty in breathing. It is an inflammatory disease that may be linked to allergens or genetic components. Long-term goals for the management of asthma are symptom control and risk reduction. Every patient should have a reliever medication (short-acting beta agonist for fast relief of symptoms), and most adults and adolescents should have a controller medication to maintain symptom control and reduce the need for reliever medications. In addition to medications, asthma treatment involves identifying and treating modifiable risk factors that can exacerbate or worsen symptoms, like smoking, allergens, etc. COPD is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. It is caused by longterm exposure to irritants or particulate matter. Traditionally, it has been associated with cigarette smoking, but other environmental irritants are associated with COPD as well. The goals for effective COPD management include preventing disease progression, relieving symptoms, improving exercise tolerance and health status, preventing and treating complications and exacerbations, and reducing overall patient mortality. Almost all patients with COPD should be prescribed long-acting bronchodilator therapy and patients with persistent symptoms should receive combination therapy. In addition to medications, COPD treatment involves identifying and treating modifiable risk factors that can exacerbate or worsen symptoms, like smoking and other environmental irritants. 11
12 Upcoming CONFERENCES & TRADESHOWS Representatives from WellDyneRx will be attending the following industry events in the near future. To schedule an onsite meeting, please contact us. CSAHU Annual Symposium June 5, 2018 Parker, CO IFEBP Trustees and Administrators Institutes June 24 27, 2018 Las Vegas, NV UFCW Local 1996 Leadership Conference June 11 13, 2018 Myrtle Beach, SC HCAA TPA Summit July 16-18, 2018 Minneapolis, MN SHRM Annual Conference & Exposition June 17-20, 2018 Chicago, IL 12
13 FDA Approval LIST Formulary management is one way to bring down drug costs, and deciding which medications to include on a formulary is part of this process. New drug releases are generally associated with higher costs, and being aware of new medications coming to market assists with cost containment. Market impact (adoption and use of a new medication) can cause drug costs to increase, but WellDyneRx helps you take proactive measures to manage your plan s drug spend. The Q FDA Approval list is shown below. Brand Name (manufacturer) Generic Name(s) Therapeutic Use Brief Description Potential Impact Rhopressa (Aerie Pharms) netarsudil ophthalmic solution 0.02% Glaucoma/Ocular Hypertension Rhopressa is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. This is the first in the class of rho kinase inhibitors believed to reduce intraocular pressure (IOP) by increasing the outflow of aqueous humor (fluid inside the eye) through the trabecular meshwork, the main fluid drain of the eye. The recommended dosage is one drop into the affected eye(s) once daily in the evening. Low Steglujan (Merck Sharp Dohme) ertugliflozinsitagliptin Type 2 Diabetes Steglujan is used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes, when treatment with both ertugliflozin and sitagliptin is appropriate. The recommended starting dose is 5mg ertugliflozin- 100mg sitagliptin once daily up to a maximum dose of 15 mg- 100mg daily. Moderate Segluromet (Merck Sharp Dohme) ertugliflozinmetformin Type 2 Diabetes Segluromet is indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are inadequately controlled on a regimen containing ertugliflozin or metformin, or in patients who are already treated with both ertugliflozin and metformin. Starting dose is individualized based on patient s current regimen with a maximum recommended dose of 7.5 mg ertugliflozin/1,000 mg metformin twice daily. Moderate Macrilen (Strongbridge Ireland) macimorelin Growth Hormone Macrilen is a ghrelin agonist indicated for the diagnosis of adult growth hormone deficiency (AGHD). The recommended dosage is a single oral dose of 0.5 mg/kg. Prior to Macrilen s approval, the historical gold standard for evaluation of AGHD was the insulin tolerance test (ITT). High 13
14 Brand Name (manufacturer) Generic Name(s) Therapeutic Use Brief Description Potential Impact Giapreza (La Jolla Pharm) angiotensin II Low-blood Pressure Giapreza is an IV infusion vasoconstrictor indicated to increase dangerously low blood pressure in adults with septic or other distributive shock. It is dosed by weight and adjusted every five minutes according to blood pressure readings. Moderate Lutathera (Advanced Accelerator Applications) lutetium Lu-177 dotatate Gastro-enteropancreatic neuroendocrine tumors Lutathera is an orphan drug and first radiopharmaceutical indicated for the treatment of adults who have gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It contains a peptide that targets cancer cells and a radioactive element that destroys them. The peptide part of Lutathera sticks to somatostatin receptors on tumor cells and then invades the cells where the radiation damages the cancer s DNA beyond repair. High Biktarvy (Gilead Sciences) bictegravir-emtricitabine-tenofovir (GEP-NETs) Biktarvy is three-drug combination indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components. The recommended dosage is one tablet once daily with or without food. Moderate Symdeko (Vertex) ivacaftortezacaftor HIV-1 Symdeko is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ ivacaftor based on in vitro data and/or clinical evidence. Dose for adults and pediatric patients is one tablet in the morning and one tablet in the evening about 12 hours apart. High 14
15 Brand Name (manufacturer) Generic Name(s) Therapeutic Use Brief Description Potential Impact Erleada (Janssen Biotech) apalutamide Prostate Cancer Erleada is an androgen receptor inhibitor indicated for the treatment of patients with nonmetastatic castration-resistant prostate cancer (NM-CRPC). This is first FDA-approved treatment for NM-CRPC; phase III clinical trial data showing a decreased risk of distant metastasis or death by 72 percent and improved metastasis-free survival by more than 2 years. The recommended dosage is 240 mg (four 60 mg tablets) once daily. High Symfi (Matrix) efavirenz-lamivudine-tenofovir disoproxil fumarate HIV-1 Symfi is a three-drug combination (a nonnucleoside reverse transcriptase inhibitor [efavirenz] and two nucleoside reverse transcriptase inhibitors), indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 40 kg. The recommended dosage is one tablet daily on an empty stomach, preferably at bedtime. Moderate Symfi Lo (Mylan) efavirenz-lamivudine-tenofovir disoproxil fumarate HIV-1 Symfi Lo is a once-daily single-tablet regimen (STR) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) in adult and pediatric patients weighing at least 35 kg. Moderate Cimduo TM (Mylan) lamivudine-tenofovir disoproxil fumarate HIV-1 Cimduo TM is a combination of two nucleoside reverse transcriptase inhibitors indicated in combination with other retroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 35 kg. The recommended daily dose is one tablet daily. Moderate 15
16 Brand Name (manufacturer) Generic Name(s) Therapeutic Use Brief Description Potential Impact Trogarzo (TaiMed Biologics) ibalizumab-uiyk HIV-1 Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor, in combination with other antiretroviral therapies, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. It works by preventing HIV from infecting CD4+ immune cells to reduce the amount of HIV in the body. This medication is administered intravenously (IV) as a single loading dose of 2,000 mg followed by a maintenance dose of 800 mg every 2 weeks. High Apadaz (KemPharm) acetaminophenbenzhydrocodone hydrochloride Pain Apadaz is an immediate-release opioid/ acetaminophen combination product indicated for the short-term (no more than 14 days) treatment of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Apadaz is chemically inactive until ingested, unlike other opioid alternatives. Treatment is initiated at 1 to 2 tablets every 4 to 6 hours as needed for pain- not to exceed 12 tablets in a 24-hour period. Low Ilumya (Merck Sharp Dohme) tildrakizumab-asmn Plaque Psoriasis Ilumya is an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This medication should only be administered by a qualified health professional and is given as a 100 mg subcutaneous (SC) dose at weeks 0, 4, and every 12 weeks thereafter. Moderate Thank you for reading the Q Well Informed. Please contact your Account Executive if you have any questions. Are You Connected? We want you to like, follow and connect with WellDyneRx. LinkedIn Twitter Facebook By connecting with WellDyneRx, you can expect useful information, rich company content and industry facts that are beneficial to you, your partners and your members. 16
June 2018 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationCovered California Formulary Analysis of Top 100 Drugs and Select Classes Prepared for the California HealthCare Foundation Avalere.
Covered California Formulary Analysis of Top 100 Drugs and Select Classes Prepared for the California HealthCare Foundation 2015 Avalere.com About the Researchers ABOUT THE CALIFORNIA HEALTHCARE FOUNDATION
More informationSpecialty conditions overview
Specialty conditions overview Prevalence and cost Click on the vials to learn more about these specialty conditions. 1. Approximate annual AWP cost per patient of top utilized drugs for UHC calendar year
More informationA MONTHLY DOSE OF EDUCATION
A MONTHLY DOSE OF EDUCATION Brian Pelletier, PharmD, BCGP, FASCP CEO, A Dose of Education, LLC December 2017 FDA Approval Ozempic (semaglutide) approved 12/5/17 A glucagon-like peptide 1 (GLP-1) receptor
More informationYou matter and so does your health.
DESCOVY is a prescription medicine that is used together with other HIV-1 medicines to treat HIV-1 in people who weigh at least 77 lbs (35kg). DESCOVY does not cure HIV-1 or AIDS. Do not use DESCOVY to
More informationDRUG TREND REPORT. WellDyneRx ANNUAL 1 2% 34% WellDyneRx. Diabetes MS Oncology Asthma/COPD HIV. Pain/inflammation. High Blood Choles Attention Disorde
WellDyneRx 34% 1 2% Inflammatory Con Diabetes MS Oncology Asthma/COPD High Blood Pressu HIV Pain/inflammation High Blood Choles Attention Disorde Inflammatory Con Diabetes MS Oncology Asthma/COPD High
More informationKEEP LOVING. Because HIV doesn t change who you are.
KEEP LOVING. Because HIV doesn t change who you are. BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in certain adults. BIKTARVY does not cure HIV-1 or AIDS. Please
More informationPERSPECTIVE THERXPIPELINE
ON PERSPECTIVE THERXPIPELINE Understanding changes in the medication market and their impact on cost and care. EnvisionRx continuously monitors the drug pipeline. As treatment options change, we evaluate
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationNEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2018/19
NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2018/19 New Medicine Product/Device Endorsement Categories A B C D E F Approved
More informationPRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March
PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking
More informationSpecialty Drugs in Workers Compensation
Specialty Drugs in Workers Compensation A GUIDE FOR CLAIMS HANDLERS Specialty Drugs Specialty drugs have been developed in response to demand for specialized medications for complex medical conditions.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Trogarzo) Reference Number: CP.PHAR.378 Effective Date: 04.17.18 Last Review Date: 05.18 Line of Business: Commercial, HIM-Medical Benefit, Medicaid Coding Implications Revision Log See
More informationMerck & Co, Inc. Announced Approval of JANUVIA TM (INN: sitagliptin), a new oral treatment of diabetes, by the US FDA
October 23, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Phone: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Phone: +81-3-6272-1001 Merck & Co, Inc. Announced Approval of JANUVIA
More informationMedia Contacts: Amy Rose Investor Contact: Graeme Bell (908) (908)
News Release FOR IMMEDIATE RELEASE Media Contacts: Amy Rose Investor Contact: Graeme Bell (908) 423-6537 (908) 423-5185 Tracy Ogden (267) 305-0960 FDA Approves Once-Daily JANUVIA, the First and Only DPP-4
More informationWell Informed. A Comprehensive Approach to Pain Management. Pain Guardian
Q1 2 0 1 7 Well Informed A Comprehensive Approach to Pain Management Use of opioids is common and necessary to support treatment for a wide variety of health related issues; however, the use of opioid
More informationMedication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationAdded, Removed or Changed. Added, Removed or Changed
One mission: you s March 8, 2018 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your
More informationMArch The 2014 Drug Trend Report Highlights
MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers
More informationMedication trends shaping workers compensation. A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes OPTUM WORKERS COMPENSATION DATA SET Analysis of our data, the industry
More informationFDA Approval LIST. WellINFORMED. Generic Name(s) Brand Name (manufacturer) Therapeutic Use. Brief Description. Potential Impact.
FDA Approval LIST Formulary management is one way to bring down drug costs, and deciding which medications to include on a formulary is part of this process. New drug releases are generally associated
More information2017 Drug Trends Series
2017 Drug Trends Series Part 1 Evaluating the traditional view Retail and mail-order prescriptions Published April 2018 1 2017 Drug Trends Series Traditional View First Script A year of important progress
More informationATS 2013 International Conference May Philadelphia Pennsylvania
American Journal of Respiratory and Critical Care Medicine American Journal of Respiratory Cell and Molecular Biology Proceedings of the American Thoracic Society STEPHEN C. CRANE, PhD, MPH Executive Director
More informationCoventry Health Care of Georgia, Inc.
Coventry Health Care of Georgia, Inc. PRESCRIPTION DRUG RIDER (for High Deductible Health Plans) This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health Plan
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More informationMagellan Rx. A smarter approach to pharmacy benefits management
Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We
More informationINTEGRATED HCV SCREENING AND TESTING IN SUBSTANCE ABUSE TREATMENT
INTEGRATED HCV SCREENING AND TESTING IN SUBSTANCE ABUSE TREATMENT HEPATITIS Hepatitis is the name for a family of viral infections that affect the liver. The most common types are Hepatitis A, B, and C.
More informationGuidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017
Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017 Scottish Health Protection Network HIV Clinical Leads FINAL Approved for circulation 17 May 2017 Version No. 6.2 (04/05/17) Date
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Enfuvirtide (Fuzeon) Reference Number: CP.PHAR.41 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationCost-Motivated Treatment Changes in Commercial Claims:
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationHIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs),
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationUp to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).
HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationDrug Class Review Monograph GPI Class 12 Antivirals
Drug Class Review Monograph GPI Class 12 Antivirals Review Time Frame: 02/2016 04/2017 Previous Class Review: 05/2016 Background: Antiviral agents are used to treat infections caused by viruses, including,
More informationViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV
ViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV ViiV Healthcare is a company 100% committed to HIV, and we are always looking to move beyond the status
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More informationJOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE
JOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE PASBO S STATEWIDE DATA STRATEGY WITH INNOVU PASBO 62 ND ANNUAL CONFERENCE AND EXHIBITS, PITTSBURGH 1 DATA STRATEGY PLATFORM 2 1 WHAT ARE
More informationSafe, effective, affordable drug choices: online tool for payers and patients.
Executive summary: Rising healthcare costs and greater access to medical information drive patients to seek options for their drug therapy. The MedAlternatives database by Gold Standard/Elsevier empowers
More informationMemo. Implications of Proposed Rule on Medicare Part D Protected Class
Memo Implications of Proposed Rule on Medicare Part D Protected Class March 11, 2019 I. Introduction Since the implementation of Medicare Part D in 2006, six classes of drugs have been protected to ensure
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationHIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.
HIV Drug Resistance Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Resistance? HIV drugs are designed to keep the amount of HIV virus
More informationDrug Guide. April New Specialty Drug Approvals. New Formulations for Existing Drugs
April 2013 The MedTrak Drug Guide provides a monthly update on recent approvals by the Food and Drug Administration (FDA). Use the chart below as a valuable reference tool. Additional detailed information
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationClinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents
Clinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents Reference: NHS England F03X08 First published: Month Year Prepared by NHS England Specialised
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationSIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item March Hepatitis
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item 12.3 28 March 2014 Hepatitis Improving the health of patients with viral hepatitis Report by the Secretariat 1. The Executive Board at
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationTherapeutic Class Indications Effective
Mortar & Pestle A Publication of Walgreens Health Initiatives July 30, 2009 A publication created especially for our clients and associates, delivering up-to-date information about brand-name and generic,
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationNew Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.
Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.
More information27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009
27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»
More informationCHAPTER - IV OBJECTIVES OF THE STUDY
CHAPTER - IV OBJECTIVES OF THE STUDY 4.1 BACKGROUND Human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) commonly referred to as HIV & AIDS have emerged as being
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationDatamonitor Healthcare Pharma intelligence. GlaxoSmithKline: Company Analysis
Datamonitor Healthcare Pharma intelligence GlaxoSmithKline: Company Analysis OVERVIEW Latest Earnings Review Q2 2018 [27 July 2018] Click to view analysis Latest Forecast Update Q2 2018 [2 August 2018]
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More information2017 Drug Trend Report Commercial Medicare Medicaid Exchanges
2017 Drug Trend Report Commercial Medicare Medicaid Exchanges Leading the way for patients and plans Our clients place a great deal of trust in Express Scripts. They ask us to care for their plan members
More informationSTELARA (ustekinumab)
STELARA (ustekinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationKaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013
Kaletra (HIV) Forecast and Market Analysis to 2022 GDHC1051DFR/ Published January 2013 Executive Summary Kaletra Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US - Kaletra 5EU
More informationThe new WHO global injection safety policy and campaign
The new WHO global injection safety policy and campaign B. Allegranzi, SDS, HIS WHO/USAID/PEPFAR hosted webinar 20 August 2015 Overuse of injections and unsafe injection practices worldwide in 2000 (1)
More informationSeptember 22, National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC Prescription Opioid Epidemic
National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC 20036 RE: Prescription Opioid Epidemic On behalf of America s Health Insurance Plans (AHIP), thank you for your leadership
More informationTRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES
POLICY BRIEF HIV TREATMENT TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES JULY 2017 WHO This policy brief provides advice on a phased approach to transitioning to new WHO-recommended HIV treatment
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More information61 Recommendations for better use of medications
Chapter 61 Recommendations for better use of medications As stated elsewhere in this book, we are fortunate to have a number of effective medications for treatment of many medical conditions. The drug
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationMerrill Lynch Healthcare Conference New York
Merrill Lynch Healthcare Conference New York Matthew Emmens Chief Executive Officer February 3, 2004 A Strategic Review Today and Beyond Clear Strengths Highly successful business model Strong pipeline
More informationIntegrating hepatitis C treatment in a regional setting The Cairns Experience. DANA 2018 Morag Goodinson
Integrating hepatitis C treatment in a regional setting The Cairns Experience DANA 2018 Morag Goodinson I would like to acknowledge the Traditional Owners of the land, and pay respect to Elders past, present
More information1. E-learning: NHIVNA HIV modules on the NHIVNA website
Vers Jan 18 E LEARNING sessions to complete for STIF NHIVNA Core Competency 1. E-learning: NHIVNA HIV modules on the NHIVNA website http://www.nhivna.org/nhivna-hiv-nursing-modules.aspx The NHIVNA HIV
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationApril 2o14. The 2013 Drug Trend Report Highlights
April 2o14 The 2013 Drug Trend Report Highlights Express Scripts Reports Lowest Specialty Drug Trend Since 2007 In 2013, spending on prescription drugs increased 5.4% after several years of slower-paced
More informationJuluca (dolutegravir, rilpivirine) NEW PRODUCT SLIDESHOW
Juluca (dolutegravir, rilpivirine) NEW PRODUCT SLIDESHOW Introduction Brand name: Juluca Generic name: Dolutegravir, rilpivirine Pharmacological class: HIV-1 integrase strand transfer inhibitor (INSTI)
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3086-5 Program Step Therapy Diabetes Medications - SGLT2 Inhibitors Medication Farxiga (dapagliflozin)*, Glyxambi (empagliflozin/linagliptan),
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationINTERNAL QUESTIONS AND ANSWERS DRAFT
WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION Background: INTERNAL QUESTIONS AND ANSWERS DRAFT At the end of 2012, 9.7 million people were receiving
More informationStarting HIV Treatment
Starting HIV Treatment August 21, 2018 Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime#thewellproject First Things First When you and your health care provider
More informationHepatitis C Virus (HCV): Current Screening Guidelines and Treatment Approaches
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/hepatitis-c-virus-hcvcurrent-screening-guidelines-treatment-approaches/9514/
More informationHEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
More informationMODERN ART FOR AFRICA
MODERN ART FOR AFRICA March 2018 A guide for HIV treatment activists and communities in lowand middle-income countries ART today A pricing agreement was recently announced that will speed up access to
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More informationProvides New Treatment Option for Stable, Virologically Suppressed Adults Living with HIV-1
MEDIA CONTACT: Rebecca Genin +1 215-620-8721 Rgenin1@its.jnj.com Kristina Chang +1 201-213-4115 Kchang12@its.jnj.com Katie Buckley +44 7971 956 179 kbuckle8@its.jnj.com INVESTOR RELATIONS: Lesley Fishman
More informationAre Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable.
Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable. BACKGROUND Your Host: Eric Bricker, MD Co-Founder & Chief Medical Officer - Compass Professional Health Services
More information@PremierHA #AdvisorLive. Download today s slides at
@PremierHA #AdvisorLive Download today s slides at www.premierinc.com/events Logistics Audio Use your computer speakers or dial in with the number on your screen Notes Download today s slides from the
More informationAsthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015
Asthma: Chronic Management Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015 Global Strategy for Asthma Management and Prevention Evidence-based Implementation
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationHMS Center for Bioethics Annual Bioethics Conference April 14, 2016
HMS Center for Bioethics Annual Bioethics Conference April 14, 2016 Panel: Social Justice Problems and Institutional Response Pharmacy/Medication Issues James J. Heffernan, MD, MPH I have no conflicts
More informationJanuary 16, Dear Administrator Verma:
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMMI New Direction P.O. Box 8011 Baltimore, MD 21244-1850 Re: (CMS-4182-P) Medicare
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More information